West Pharmaceutical Services (WST) is a Top-Ranked Growth Stock: Should You Buy?
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike.
Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term.
Why This 1 Growth Stock Should Be On Your Watchlist
Different than value or momentum investors, growth-oriented investors are concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, they'll want to focus on the Growth Style Score, which analyzes characteristics like projected and historical earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
West Pharmaceutical Services (WST)
West Pharmaceutical Services Inc. is a leading global manufacturer with respect to design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. The Exton, PA-based company designs and produces these medical products in the Americas, Europe, the Middle East, Africa and the Asia Pacific. Its primary objective is to deliver quality products that cater to the exact product specifications and quality standards that customers expect and need. West Pharmaceutical operates through two segments – Proprietary Products and Contract-Manufactured Products.
WST is a Zacks Rank #3 (Hold) stock, with a Growth Style Score of B and VGM Score of B. Earnings are expected to grow 8.5% year-over-year for the current fiscal year, with sales growth of 8%.
Four analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.03 to $9.31 per share for 2022. WST boasts an average earnings surprise of 16.6%.
On a historic basis, West Pharmaceutical Services has generated cash flow growth of 25.1%, and is expected to report cash flow expansion of 65.6% this year.
With solid fundamentals, a good Zacks Rank, and top-tier Growth and VGM Style Scores, WST should be on investors' short lists.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
